Arriagada, R., Auperin, A., Burdett, S., Higgins, J.P., Johnson, D.H., Le Chevalier, T., Le Pechoux, C., Pamar, M.K., Pignon, P.J., Souhami, R.L., Stephens, R.J., Stewart, L.A., Tierney, J.F., Tribodet, H. and van Meerbeeck, J., On Behalf of the NSCLC Meta-Analyses Collaborative Group (2010) Adjuvant Chemotherapy with or witout Postoperative Radiotherapy in Operable Non-Small-Cell Lung Cancer: Two Meta-Analyses of Individual Patient Data. Lancet, 375, 1267-1277. http://dx.doi.org/10.1016/S0140-6736(10)60059-1

has been cited by the following article:

• TITLE: Fixed Dose Rate versus Standard Dose Rate Infusion of Gemcitabine and Cisplatin in Advanced Stage Non-Small Cell Lung Cancer

  AUTHORS: Dina A. Salem, Dina R. Ibrahim, Ahmed Ezzat, Azza M. Adel

  KEYWORDS: Non-Small Cell Lung Cancer, Gemcitabine, Fixed-Dose Rate, Toxicities

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.1, January 8, 2015

  ABSTRACT: Background: Comparing the efficacy and safety of gemcitabine at a fixed-dose rate (FDR) infusion (10 mg/m2/min) with the standard dose rate infusion in patients with locally advanced and metastatic non-small squamous cell carcinoma (NSCLC). Methods: The study randomized 60 patients with confirmed diagnosis of NSCLC to receive gemcitabine at a dose of 1000 mg/m2 on days 1 and 8 given as a 30-min infusion (Arm A) or at a rate of 10 mg/m2/min (Arm B). Cisplatin 75 mg/m2 was administered intravenously on day 2 in both arms. Results: No difference in overall response rate (46.6% versus 43.3%). Median time to progression for Arm A was 7 months (95% CI, 6.207 - 7.793 months), versus 6 months for Arm B (95% CI, 4.990 - 7.010 months). Median survival time was comparable [12 months (95% CI, 8.588 - 15.412 months) versus 11 months (95% CI, 9.066 - 12.934 months)] respectively. Two-year survival (18% versus 11%, p = 0.38) was detected. No treatment related deaths occurred. Main hematological toxicities were grade I and II neutropenia, in 36.7% and 53.3% respectively (p = 0.044). Grade III anemia was observed in 10% and 6.7% in both arms respectively (p = 0.024). Grade I and II nausea and vomiting was observed in 50% and 46.7%. Conclusions: FDR gemcitabine in combination with cisplatin had equivalent efficacy and more severe hematologic toxicities compared to the standard 30-min gemcitabine infusion with cisplatin in patients with advanced NSCLC.